Identifying biomarkers that can be used as diagnostics or predictors of treatment response
(theranostics) in people with schizophrenia (Sz) will be an important step towards being able
to provide personalized treatment. Findings from the studies in brain tissue have not yet
been translated into biomarkers that are practical in clinical use because brain biopsies are
not acceptable and neuroimaging techniques are expensive and the results are
inconclusive. Thus, in recent years, there has been search for blood-based biomarkers for …